Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.27 and traded as low as $0.26. Northwest Biotherapeutics shares last traded at $0.27, with a volume of 1,256,348 shares trading hands.
Northwest Biotherapeutics Trading Up 0.3%
The company has a 50-day moving average of $0.27 and a 200-day moving average of $0.27. The company has a market capitalization of $393.52 million, a price-to-earnings ratio of -3.40 and a beta of -0.81.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last announced its earnings results on Thursday, May 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.38 million during the quarter.
About Northwest Biotherapeutics
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Further Reading
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
